Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

M6620

(adavosertib)

Phase 2Small molecule

Adavosertib is being studied as a cancer treatment that works by stopping cancer cells from repairing their DNA damage, making them more vulnerable to chemotherapy and radiation.[1] M6620 is currently being investigated across 9 indications[3], with its most advanced program in Phase 2.[1]

M6620 is one of 148 small molecule programs targeting Pediatric Cancer. It is currently in Phase 2.

9

Indications

28

Total Trials

10

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pediatric CancerRecruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8Active, not recruiting

Recurrent Fallopian Tube CarcinomaActive, not recruiting

Advanced LymphomaActive, not recruiting

Ovarian Brenner TumorActive, not recruiting

Patients With Advanced Solid TumorsActive, not recruiting

Primary Peritoneal CancerCompleted

Clear Cell Renal Cell CarcinomaActive, not recruiting

Prostate CancerActive, not recruiting

Pediatric CancerPreclinical

Recruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8Phase 1

Active, not recruiting

Recurrent Fallopian Tube CarcinomaPhase 2

Active, not recruiting

Advanced LymphomaPhase 2

Active, not recruiting

Ovarian Brenner TumorPhase 2

Active, not recruiting

Patients With Advanced Solid TumorsPhase 1

Active, not recruiting

Primary Peritoneal CancerPhase 2

Completed

Clear Cell Renal Cell CarcinomaPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Alinamin

Orgovyx

Sumitomo Pharma America, Inc.

M6620

Semaglutide Pen Injector

UUniversitaire Ziekenhuizen KU Leuven

Gallium Ga 68 Gozetotide

Antibiotic Prophylaxis

AAssistance Publique - Hôpitaux de Paris

Trexall

Jazz Pharmaceuticals

Duragesic

Ranexa

MMenarini International Operations Luxembourg SA

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Patients With Advanced Solid Tumors

NCT04197713

Q4 2026

Phase 1Active, not recruiting

Clinical Stage III Esophageal Adenocarcinoma AJCC V8

NCT04460937

Phase 1Active, not recruiting

Primary Peritoneal Cancer

NCT02659241

Phase 2Active, not recruiting

Advanced Lymphoma

NCT02465060

Phase 2Active, not recruiting

Advanced Lymphoma

NCT04439227

Phase 2Active, not recruiting

Recurrent Fallopian Tube Carcinoma

NCT03579316

Clinical

Trials by Indication[1]

Advanced Solid Tumours2 trials

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT04949425·3 enrolled

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT04462952·6 enrolled

Primary Peritoneal Cancer2 trials

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02272790·95 enrolled

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02659241·38 enrolled

Advanced Lymphoma2 trials

Molecular Analysis for Therapy Choice (MATCH)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled

MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients With Tumors Containing BRCA1 and BRCA2 Mutations

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04439227·33 enrolled

Tics1 trial

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT04959266·5 enrolled

Glioblastoma1 trial

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01849146·74 enrolled

20 more indications

Advanced Refractory Solid Tumors1 trial

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03253679·31 enrolled

Absorption1 trial

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT05008913·2 enrolled

Advanced Solid Tumor1 trial

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT01047007·11 enrolled

Serous Carcinoma1 trial

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT04590248·109 enrolled

Uterine Cancer1 trial

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03345784·10 enrolled

Refractory Solid Tumors1 trial

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT02095132·76 enrolled

Ovarian Tumor1 trial

A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01357161·136 enrolled

Advanced Solid Tumors1 trial

A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00648648·206 enrolled

Patients With Advanced Solid Tumors1 trial

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04197713·13 enrolled

Acute Myeloid Leukemia1 trial

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT02381548·20 enrolled

Tumor1 trial

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01827384·208 enrolled

Prostate Cancer1 trial

Prostate Cancer Biomarker Enrichment and Treatment Selection

Active, not recruiting·CCanadian Cancer Trials Group·Phase 2·NCT03385655·200 enrolled

Cervical Cancer1 trial

A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT01076400·7 enrolled

Diffuse Intrinsic Pontine Glioma1 trial

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01922076·46 enrolled

Gemcitabine1 trial

Adavosertib and Gemcitabine in Advanced Pancreatic

Withdrawn·—·Phase 2·NCT05212025

Ovarian Brenner Tumor1 trial

A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02101775·124 enrolled

Clinical Stage III Esophageal Adenocarcinoma AJCC v81 trial

A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04460937·4 enrolled

Clear Cell Renal Cell Carcinoma1 trial

A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03284385·18 enrolled

Recurrent Fallopian Tube Carcinoma1 trial

EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03579316·96 enrolled

Pediatric Cancer1 trial

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Preclinical·NCT02813135·472 enrolled

Sources

References

[1]
ClinicalTrials.gov — 28 trial records for adavosertib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — adavosertib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for adavosertib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Serine/threonine-Protein Kinase WEE1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Related News